Investigation of the Role of Interleukin 6 in Vitiligo Pathogenesis.


Journal

Immunological investigations
ISSN: 1532-4311
Titre abrégé: Immunol Invest
Pays: England
ID NLM: 8504629

Informations de publication

Date de publication:
Jan 2022
Historique:
pubmed: 1 9 2020
medline: 5 2 2022
entrez: 1 9 2020
Statut: ppublish

Résumé

Interleukin-6 (IL6) is involved in pathogenesis of several autoimmune disorders including vitiligo. Hence, we aimed to investigate the association of IL6 -174 G/C and -572 G/C polymorphisms and its transcript levels with vitiligo; to evaluate the effect of IL-6 on normal human melanocyte (NHM) viability and expression of IL6R, MITF and TYR. IL6 -174 G/C and -572 G/C polymorphisms were genotyped by ARMS-PCR and PCR-RFLP respectively in 343 controls and 322 vitiligo patients. IL6 transcript levels were estimated from PBMCs (96 controls and 77 patients) and skin samples (15 controls and 15 patients) by qPCR. NHM viability was assessed by MTT; IL6R, MITF and TYR transcript and protein levels were monitored by qPCR and ICC respectively. Genetic analyses revealed no association of IL6 -174 G/C polymorphism (p> .05) with vitiligo. Analysis of IL6 -572 G/C revealed reduced risk of vitiligo in individuals with GC/CC genotypes compared to GG genotype (p = .010). IL6 expression was significantly increased (p = .0197) in PBMCs of patients. Further, IL6 expression was significantly higher in non-lesional skin compared to controls (p = .009). In-vitro NHM viability was decreased upon IL-6 exposure (10-50 ng/ml; p< .05), with significantly increased IL6R transcript (p = .042) and protein levels (p = .003) however, MITF transcript (p = .0003) and protein levels (p = .016), and TYR transcript levels (p = .001) were significantly decreased. The results suggest that IL6 -572 G/C polymorphism might be associated with vitiligo susceptibility in Gujarat population. Moreover, increased IL6 expression in vitiligo patients and its effect on NHM suggest a potential role in melanocyte biology. The results suggest that

Identifiants

pubmed: 32865069
doi: 10.1080/08820139.2020.1813756
doi:

Substances chimiques

IL6 protein, human 0
Interleukin-6 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

120-137

Auteurs

Mala Singh (M)

Department of Biochemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Gujarat, Vadodara, India.

Shahnawaz D Jadeja (SD)

Department of Biochemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Gujarat, Vadodara, India.

Jayvadan Vaishnav (J)

Department of Biochemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Gujarat, Vadodara, India.

Mohmmad Shoab Mansuri (MS)

Department of Biochemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Gujarat, Vadodara, India.

Chandni Shah (C)

Department of Biochemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Gujarat, Vadodara, India.

Jay M Mayatra (JM)

Department of Biochemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Gujarat, Vadodara, India.

Atul Shah (A)

Department of Reconstructive Surgery, Solace Hospital, Vadodara, India.

Rasheedunnisa Begum (R)

Department of Biochemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Gujarat, Vadodara, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH